TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27974950

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 20mg/kg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 24661817

Group type: EXPERIMENTAL
Intervention: Nebulized heparin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 116
Study: 23046784

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supportive Counseling
Number of subjects: 30
Study: 20194883

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Weight loss (overall)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Weight loss (carotid VWV regression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Weight loss (carotid VWV progression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure change (carotid VWV regression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure change (carotid VWV progression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Total homocysteine change (carotid VWV regression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Total homocysteine change (carotid VWV progression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1 change (carotid VWV regression)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A1 change (carotid VWV progression)
Number of subjects: 140
Study: 17507321

Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) regimen
Number of subjects: 96
Study: 16133484

Group type: COMPARATOR
Intervention: Non-ionic Gd-DTPA-BMA/gadodiamide (0.1 mmol/kg body weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ionic Gd-DTPA/gadopentetate (0.1 mmol/kg body weight)
Number of subjects: 40
Study: 11896513

Group type: EXPERIMENTAL
Intervention: > or =3 courses of antenatal corticosteroids (ANCS)
Number of subjects: 595

Group type: COMPARATOR
Intervention: 1 or 2 courses of antenatal corticosteroids (ANCS)
Number of subjects: 595
Study: 12166718

Group type: EXPERIMENTAL
Intervention: Prodigy Condensable (P)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Definite (D)
Number of subjects: 36
Study: 9822949

Group type: EXPERIMENTAL
Intervention: six-month behavioral weight loss intervention, delivered via correspondence
Number of subjects: 90

Group type: COMPARATOR
Intervention: no-treatment control group
Number of subjects: 90
Study: 7860418

Group type: EXPERIMENTAL
Intervention: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 4 mg/day testosterone replacement
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 7.5 mg of a long-acting GnRH agonist microcapsule formulation (Lupron Depot) on days 1 and 30; 8 mg/day testosterone replacement
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control period (3 weeks)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Treatment period (9 weeks)
Number of subjects: 2
Study: 2468962

Group type: EXPERIMENTAL
Intervention: PK 11195 (200 mg orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of PK 11195 and Nicardipine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 913294

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-triamterene (25 and 50 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propranolol (160 mg/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-triamterene added to Propranolol
Number of subjects: 36
Study: 6782605

Group type: EXPERIMENTAL
Intervention: IV physostigmine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31295292

Group type: EXPERIMENTAL
Intervention: Therapeutic footwear with a rigid rocker sole
Number of subjects: 51

Group type: COMPARATOR
Intervention: Therapeutic footwear with semi-rigid sole (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Therapeutic footwear with a rigid rocker sole (among >60% adherence group)
Number of subjects: 51
Study: 30566019

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study: 27336726

Group type: EXPERIMENTAL
Intervention: Ribociclib (400 mg/day) plus letrozole (2.5 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day) plus letrozole (2.5 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/day) alone
Number of subjects: 14
Study: 25027304

Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI at 14.4, 28.8, 57.6, and 115.2 μg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tiotropium (TIO) 18 μg
Number of subjects: 33
Study: 22070446

Group type: EXPERIMENTAL
Intervention: IUI by passive straightening of the uterus by means of bladder filling
Number of subjects: 460

Group type: COMPARATOR
Intervention: IUI performed with an empty bladder (control)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Easy IUI (full bladder)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Difficult IUI (empty bladder)
Number of subjects: 460
Study: 20417445

Group type: EXPERIMENTAL
Intervention: Intensive care programme managed by trained nurses; intervention lasted for 1 year with visits every 6 weeks for standardized BP measurement, self‐measurement training, risk factor checks and advice on BP reduction.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care; control group.
Number of subjects: 200
Study: 18577933

Group type: EXPERIMENTAL
Intervention: Berlition (contains a-lipoic acid) used in neuroprotective therapy for chronic brain ischemia
Number of subjects: 0
Study: 15844495

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 mcg twice daily, commencing 6 weeks after FESS
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 14624183

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10482177

Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 20 mg every 8 hours
Number of subjects: 11733

Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 80 mg every 8 hours
Number of subjects: 11733

Group type: EXPERIMENTAL
Intervention: Intravenous cariporide 120 mg every 8 hours
Number of subjects: 11733

Group type: COMPARATOR
Intervention: Placebo every 8 hours
Number of subjects: 11733

Group type: EXPERIMENTAL
Intervention: All treatment groups (cariporide and placebo)
Number of subjects: 11733
Study: 8728458

Group type: EXPERIMENTAL
Intervention: Extension-rotation test
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 42
Study: 1867090

Group type: EXPERIMENTAL
Intervention: Materially deprived children
Number of subjects: 234

Group type: COMPARATOR
Intervention: Other children
Number of subjects: 234
Study: 6634348

Group type: EXPERIMENTAL
Intervention: Group 1 received a random order of six numbers (5, 10, 15, 20, 25, 30) for magnitude production.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group 2 received the same random series of six numbers as Group 1, but with additional numbers interspersed to present an expanded range.
Number of subjects: 20
Study: 30876982

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS at 2 mA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS at 1 mA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 29995455

Group type: EXPERIMENTAL
Intervention: Rifaximin‐α 550 mg twice daily plus lactulose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactulose alone
Number of subjects: 0
Study: 27584836

Group type: EXPERIMENTAL
Intervention: Community-based integrated intervention (social skills training plus Tai-chi)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Medication treatment alone (MTA group)
Number of subjects: 244
Study: 24527846

Group type: EXPERIMENTAL
Intervention: 0.1% pilocarpine mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study: 22197676

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 586

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 586
Study: 19395187

Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant ADT before RT
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 8 months of neoadjuvant ADT before RT
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: High-risk patients with PRPH-PSA <=0.1 ng/ml
Number of subjects: 378

Group type: COMPARATOR
Intervention: PRPH-PSA
Number of subjects: 378

Group type: COMPARATOR
Intervention: Gleason score
Number of subjects: 378

Group type: COMPARATOR
Intervention: Initial PSA
Number of subjects: 378

Group type: COMPARATOR
Intervention: T-stage
Number of subjects: 378
Study: 17297298

Group type: COMPARATOR
Intervention: Conventional schedule (Group C; N = 73, vaccination on days 0, 28 and 300)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Modified conventional schedule (Group M; N = 139, vaccination on days 0, 21 and 300)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Rapid schedule (Group R; N = 82, vaccination on Days 0, 7 and 21)
Number of subjects: 294
Study: 16118920

Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy (FT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with deep nonperforative sclerectomy (FS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with iridocleisis (FW)
Number of subjects: 50
Study: 12832939

Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Termination of pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective termination of multifetal pregnancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonaggressive management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalocentesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetal research
Number of subjects: 0
Study: 10575280

Group type: EXPERIMENTAL
Intervention: Complementary medical procedures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Health insurance reimbursement of complementary medical procedures
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cost developments
Number of subjects: 10
Study: 8596594

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 1785031

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (1.0 watt/cm2 at 1 MHz, for 10 min) twice weekly for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 38
Study: 6101791

Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon (12 x 10(6) reference units daily for the first week, then halved weekly for six weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (8 patients not receiving interferon)
Number of subjects: 16
Study: 31969362

Group type: EXPERIMENTAL
Intervention: CT group (offered annual CT screening, lung function test and smoking counselling)
Number of subjects: 4639

Group type: COMPARATOR
Intervention: Control group (offered annual lung function test and smoking counselling)
Number of subjects: 4639
Study: 29888943

Group type: EXPERIMENTAL
Intervention: Comparing a present stimulus to a previously encountered source stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparing two simultaneously present stimuli
Number of subjects: 0
Study: 26687330

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 8050

Group type: COMPARATOR
Intervention: Standard Case Management (SCM)
Number of subjects: 8050
Study: 24928217

Group type: EXPERIMENTAL
Intervention: SLIMMER intervention (dietary and physical activity intervention, including case management and a maintenance programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual health care and written information about a healthy lifestyle (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLIMMER intervention
Number of subjects: 0
Study: 23265006

Group type: EXPERIMENTAL
Intervention: Decreased Reaction Time group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Increased Reaction Time group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 20586550

Group type: COMPARATOR
Intervention: Tibolone (T)
Number of subjects: 0
Study: 19014790

Group type: EXPERIMENTAL
Intervention: Contraceptive Patch (CP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Contraceptive Ring (CR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of CP vs CR at Cycle 4
Number of subjects: 120
Study: 16292092

Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 x 7 Gy brachytherapy
Number of subjects: 60
Study: 12023993

Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic oophorectomy
Number of subjects: 551

Group type: COMPARATOR
Intervention: Control group (no prophylactic oophorectomy)
Number of subjects: 551
Study: 10522500

Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid (Cellex‐C high‐potency serum)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle control serum
Number of subjects: 19
Study: 8746883

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily) + Calcium (1000 mg daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium (1000 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 25
Study: 1838079

Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 1.5 mg on days 1‐12 and 17 beta‐oestradiol 1.5 mg + desogestrel 150 micrograms on days 13‐24 (E2/DG)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: oestradiol valerate 2 mg on days 1‐11 and oestradiol valerate 2 mg + medroxyprogesterone acetate 10 mg on days 12‐21 (E2V/MPA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 7193582

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine, 50 mg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 34
Study: 31492178

Group type: EXPERIMENTAL
Intervention: Inclusion of pregnant women in clinical trials for pregnancy complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research participation for unborn babies with complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research participation for newborns
Number of subjects: 0
Study: 28803030

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham neurofeedback
Number of subjects: 118

Group type: COMPARATOR
Intervention: Meta-cognitive therapy
Number of subjects: 118
Study: 26109630

Group type: EXPERIMENTAL
Intervention: S-1 plus irinotecan (oral S-1 40-60 mg/m² on days 1-14 and intravenous irinotecan 150 mg/m² on day 1 of a 21-day cycle)
Number of subjects: 304

Group type: COMPARATOR
Intervention: irinotecan-alone (intravenous irinotecan 150 mg/m² on day 1 of a 14-day cycle)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: S-1 plus irinotecan
Number of subjects: 304

Group type: COMPARATOR
Intervention: irinotecan-alone
Number of subjects: 304
Study: 23637556

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Hydrochlorothiazide 25 mg (T80/H25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telmisartan 80 mg (T80)
Number of subjects: 0
Study: 20499107

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Men's symptoms
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sexual bother
Number of subjects: 43
Study: 19288570

Group type: EXPERIMENTAL
Intervention: FOBT (Hemoccult II) sensitivity at the stage of clinical diagnosis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: FOBT (Hemoccult II) sensitivity in earlier stages
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Average duration of preclinical CRC
Number of subjects: 3
Study: 16678551

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg per day for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15225889

Group type: EXPERIMENTAL
Intervention: Nicotine pretreatment via a transdermal patch (21 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol administration (0.4 and 0.7 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study: 11295031

Group type: EXPERIMENTAL
Intervention: Standard dialysis dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dialysis dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dialysis membrane flux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dialysis membrane flux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional monitoring by dietitian
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0
Study: 9207355

Group type: EXPERIMENTAL
Intervention: Sorivudine 40 mg once daily for 7 days
Number of subjects: 125

Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 125
Study: 8126036

Group type: EXPERIMENTAL
Intervention: 4.0‐millimeter orientruded polylactide screws (study group, n=83)
Number of subjects: 155

Group type: COMPARATOR
Intervention: 4.0‐millimeter stainless‐steel screws (control group, n=72)
Number of subjects: 155
Study: 2572205

Group type: EXPERIMENTAL
Intervention: bromocriptine plus neuroleptic
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 30113736

Group type: EXPERIMENTAL
Intervention: 2% clindamycin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2% triple antibiotic paste (TAP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100% triple antibiotic paste (TAP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methylcellulose (control)
Number of subjects: 100
Study: 24458199

Group type: EXPERIMENTAL
Intervention: 300-mg sustained-release tablet (SRT) of ONO-5334
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Repeated dosing of 300-mg sustained-release tablet (SRT) of ONO-5334
Number of subjects: 33

Group type: COMPARATOR
Intervention: 300-mg immediate-release tablet (IRT) of ONO-5334
Number of subjects: 33
Study: 23111466

Group type: EXPERIMENTAL
Intervention: Diagnostic interviews conducted by two clinicians who were blind to previous diagnoses.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Usual clinical interview methods used for assessment.
Number of subjects: 23
Study: 21435695

Group type: EXPERIMENTAL
Intervention: CHF decompensation
Number of subjects: 11681

Group type: EXPERIMENTAL
Intervention: CHF compensation
Number of subjects: 11681

Group type: EXPERIMENTAL
Intervention: Diuretic initiation
Number of subjects: 11681

Group type: EXPERIMENTAL
Intervention: Diuretic discontinuation
Number of subjects: 11681
Study: 18978621

Group type: EXPERIMENTAL
Intervention: Gymnasts
Number of subjects: 38

Group type: COMPARATOR
Intervention: Male runners
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Female gymnasts
Number of subjects: 38

Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 38

Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 38
Study: 16814206

Group type: EXPERIMENTAL
Intervention: Experimental procedure (liquid‐based cytology and testing for high‐risk HPV types)
Number of subjects: 11810

Group type: EXPERIMENTAL
Intervention: HPV testing (> or = 1 pg/mL) with cytology triage
Number of subjects: 11810

Group type: EXPERIMENTAL
Intervention: Liquid‐based cytology
Number of subjects: 11810

Group type: COMPARATOR
Intervention: Conventional procedure (standard cytology)
Number of subjects: 11810
Study: 12763513

Group type: EXPERIMENTAL
Intervention: Combined oral hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10721594

Group type: EXPERIMENTAL
Intervention: Walsh and Ogura technique
Number of subjects: 17

Group type: COMPARATOR
Intervention: Kennedy's surgical approach
Number of subjects: 17
Study: 8868968

Group type: EXPERIMENTAL
Intervention: Group therapy with adolescents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled outcome studies
Number of subjects: 0
Study: 1658652

Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg twice a day for one week, followed by 5 mg/kg per day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 72
Study: 6350071

Group type: EXPERIMENTAL
Intervention: Tioconazole 1% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miconazole 2% cream applied twice daily for 14 days (pityriasis versicolor) or 28 days (dermatophyte and yeast infections)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tioconazole for infections with Trichophyton rubrum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miconazole for infections with Trichophyton rubrum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tioconazole long-term follow-up
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miconazole long-term follow-up
Number of subjects: 60
Study: 31200505

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo nitrate-depleted BJ (PLA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Orange flavored non-caloric drink (OFD)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All interventions (BJ, PLA, OFD)
Number of subjects: 13